MIRIPLATIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	2C14H27O2.C6H14N2.Pt
Molecular Weight	763.999
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Pt++].N[C@@H]1CCCC[C@H]1N.CCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCC([O-])=O

InChI

InChIKey=BGIHRZPJIYJKAZ-BLUNCNMSSA-L

InChI=1S/2C14H28O2.C6H14N2.Pt/c2*1-2-3-4-5-6-7-8-9-10-11-12-13-14(15)16;7-5-3-1-2-4-6(5)8;/h2*2-13H2,1H3,(H,15,16);5-6H,1-4,7-8H2;/q;;;+2/p-2/t;;5-,6-;/m..1./s1

HIDE SMILES / InChI

Description
Sources: https://www.sumitomo-chem.co.jp/english/rd/report/theses/docs/2011-1E_04.pdf | http://www.ds-pharma.com/ir/news/pdf/ene20091215.pdf

Miriplatin is a novel lipophilic platinum complex that was developed to treat hepatocellular carcinoma (HCC). Miriplatin hydrate was approved by Pharmaceuticals and Medical Devices Agency of Japan (PMDA) on Oct 16, 2009. It was developed and marketed as Miripla® by Dainippon Sumitomo Pharma on Jan 20, 2010 in Japan. Miriplatin hydrate is a lipophilic platinum complex that has high affinity to lipiodol. It is indicated for the treatment of transcatheter arterial chemoembolization of hepatocellular carcinoma. Miripla® is available as lyophilized powder for arterial injection, containing 70 mg of free Miriplatin. The recommended dose is 70 mg once daily.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA 278 Target ID: CHEMBL2311221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10744050 \| http://adisinsight.springer.com/drugs/800003094	Crosslinking Agent 81

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hepatocellular carcinoma 83 Sources: http://www.ds-pharma.com/ir/news/pdf/ene20091016.pdf http://adisinsight.springer.com/drugs/800003094	Primary		Approved 8429	MIRIPLA Approved Use Lipiodolization in hepatocellular carcinoma Launch Date 2009

PubMed

Title	Date	PubMed
In vitro antitumor activity, intracellular accumulation, and DNA adduct formation of cis-[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)] platinum (II) suspended in lipiodol.	2000 Jan	10744050
In vitro release of SM-11355, cis[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)] platinum(II) suspended in lipiodol.	2000 May	10823679
Relation between intracellular accumulation and cytotoxic activity of cis-[((1R, 2R)-1, 2-cyclohexanediamine-N, N')bis(myristato)]platinum(II) suspended in Lipiodol.	2003 May	12736512
Warming effect on miriplatin-lipiodol suspension for potential use as a chemotherapeutic agent for transarterial chemoembolization of hepatocellular carcinoma: In vitro study.	2013 Oct	23347354

Patents

Sample Use Guides

In Vivo Use Guide

70 mg of miriplatin is suspended in 3.5 mL of suspension vehicle for this drug, and administered once a day through catheter inserted into hepatic artery. Administration of miriplatin-suspension ends when tumor vessel is filled with the drug, provided that the upper limit should be 6 mL per administration (equivalent to 120 mg of miriplatin). An observation period of 4 weeks or longer is required in the case of repeated administration.

Route of Administration: Intra-arterial

In Vitro Use Guide

Miriplatin (SM-11355) suspended in Lipiodol (SM-11355/Lipiodol) showed cytotoxic activity against rat ascites hepatoma AH-109A cells in a dose-dependent manner. IC50 value following 7-day exposure was 22.3 ug/ml.

Name

Type

Language

MIRIPLATIN

Official Name

English

SM-11355

Code

English

MIRIPLA

Brand Name

English

Miriplatin [WHO-DD]

Common Name

English

MIRIPLATIN [MI]

Common Name

English

CYCLOHEXANE-(1R,2R)-DIAMINEPLATINUM(II) DIMYRISTATE

Common Name

English

miriplatin [INN]

Common Name

English

Code System Code Type Description

EVMPD

SUB34987